HCM vs NHC

HCM presents a contradictory profile: it is fundamentally undervalued based on deterministic metrics, with a Piotroski F-Score of 5/9 (Stable) and a current price ($15.24) well below both its Graham Number ($20.72) and Intrinsic Value ($18.55). However, the company's operational health is concerning, characterized by negative revenue growth (-16.5%) and a severe collapse in earnings (-98.1% YoY). While the balance sheet is exceptionally strong with very low debt and high liquidity, the core business is currently unprofitable at the operating level. The investment case relies on a turnaround or a catalyst to realize the analyst target price of $22.85.

NHC exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a nearly debt-free balance sheet (Debt/Equity 0.08). While the stock trades below its growth-based intrinsic value of $226.26, it is currently priced above its defensive Graham Number of $108.96. The outlook is tempered by a concerning Forward P/E of 403.00 and a streak of four consecutive earnings misses, suggesting a significant projected decline in profitability. Despite strong long-term price appreciation, the current technical trend is heavily bearish (10/100), indicating a potential short-term reversal or consolidation phase.